Clinical Trial Update: A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) [Phase 3]

View source ↗

Summary

Phase 3 study of VX-445 combination therapy in cystic fibrosis patients with F508del/F508del has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-445

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2020-01-27